UY29663A1 - Complejos metalicos con contenido de perfluoroalquilo, procedimientos para su preparacion, así como su uso - Google Patents

Complejos metalicos con contenido de perfluoroalquilo, procedimientos para su preparacion, así como su uso

Info

Publication number
UY29663A1
UY29663A1 UY29663A UY29663A UY29663A1 UY 29663 A1 UY29663 A1 UY 29663A1 UY 29663 A UY29663 A UY 29663A UY 29663 A UY29663 A UY 29663A UY 29663 A1 UY29663 A1 UY 29663A1
Authority
UY
Uruguay
Prior art keywords
preparation
content
perfluoroquilo
procedures
well
Prior art date
Application number
UY29663A
Other languages
English (en)
Inventor
Ludwig Zorn
Bernd Misselwitz
Thomas Brumby
Johannes Platzek
Heiko Schirmer
Hanns-Joachim Weinmann
Jorg Meding
Heribert Schmitt-Willich
Original Assignee
Schering Ag
Epix Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102005033903A external-priority patent/DE102005033903B4/de
Application filed by Schering Ag, Epix Pharm Inc filed Critical Schering Ag
Publication of UY29663A1 publication Critical patent/UY29663A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencinn se refiere a los objetos caracterizados en las reivindicaciones, a saber, complejos metrlicos con contenido de perfluoroalquilo con grupo N-alquino de la fnrmula general I, a procedimientos para su preparacinn y a su uso en el diagnnstico por RMN y rayos X, en el radiodiagnnstico y la radioterapia, ase como en la linfografia MRT.-
UY29663A 2005-07-15 2006-07-11 Complejos metalicos con contenido de perfluoroalquilo, procedimientos para su preparacion, así como su uso UY29663A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005033903A DE102005033903B4 (de) 2005-07-15 2005-07-15 Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel
EP05090230 2005-08-10

Publications (1)

Publication Number Publication Date
UY29663A1 true UY29663A1 (es) 2007-02-28

Family

ID=38813200

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29663A UY29663A1 (es) 2005-07-15 2006-07-11 Complejos metalicos con contenido de perfluoroalquilo, procedimientos para su preparacion, así como su uso

Country Status (10)

Country Link
US (1) US20070020183A1 (es)
EP (1) EP1904462A2 (es)
JP (1) JP2009509915A (es)
CA (1) CA2615434A1 (es)
DO (1) DOP2006000166A (es)
GT (1) GT200600314A (es)
PE (1) PE20070363A1 (es)
TW (1) TW200740777A (es)
UY (1) UY29663A1 (es)
WO (1) WO2007009637A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618957B2 (en) * 2005-07-15 2009-11-17 Bayer Schering Pharma Aktiengesellschaft Perfluoroalkyl-containing complexes, process for their production as well as their use
DE102007015598A1 (de) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
US7810965B2 (en) 2008-03-02 2010-10-12 Lumenetix, Inc. Heat removal system and method for light emitting diode lighting apparatus
US7969075B2 (en) 2009-02-10 2011-06-28 Lumenetix, Inc. Thermal storage system using encapsulated phase change materials in LED lamps
US8760265B2 (en) * 2009-05-08 2014-06-24 Apple Inc. Remote control signal learning and processing by a host device and accessory
KR101811116B1 (ko) * 2013-05-09 2017-12-20 캐논 가부시끼가이샤 화합물, 광경화성 조성물, 및 광경화성 조성물을 사용하여 패턴 형상을 갖는 막, 광학 부품, 회로 기판, 전자 부품을 제조하는 방법, 및 경화물
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
WO2018204872A2 (en) 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
RU2019139432A (ru) 2017-05-05 2021-06-07 Сентр фор Проуб Девелопмент энд Коммерсиализэйшн Фармакокинетическая оптимизация бифункциональных хелатов и их применение
CN114181164A (zh) * 2021-12-13 2022-03-15 武汉大学中南医院 基于Fe(Ⅱ)特异性MRI对比剂的合成方法及其应用
CN114085619B (zh) * 2021-12-23 2022-07-15 泰州亚德胶粘制品有限公司 一种耐高温低粘着光学胶粘剂及其制备方法
CN115308319A (zh) * 2022-06-28 2022-11-08 北京大学 一种全氟及多氟烷基化合物非靶向筛查的定量方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641797B2 (en) * 2000-08-11 2003-11-04 Schering Aktiengesellschaft Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use
DE10040858C2 (de) * 2000-08-11 2003-12-18 Schering Ag Perfluoralkylhaltige Komplexe mit polaren Resten, Verfahren zu deren Herstellung und ihre Verwendung
US6676928B2 (en) * 2000-08-11 2004-01-13 Schering Aktiengesellschaft Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use
DE10040381C1 (de) * 2000-08-11 2002-06-06 Schering Ag Perfluoralkylhaltige Komplexe mit Zuckerresten, Verfahren zu deren Herstellung und ihre Verwendung
US6818203B2 (en) * 2000-08-11 2004-11-16 Schering Aktiengesellschaft Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses
US7334704B1 (en) * 2005-01-25 2008-02-26 William C Bynum Apparatus for flattening the walls of flexible tubes
US7618957B2 (en) * 2005-07-15 2009-11-17 Bayer Schering Pharma Aktiengesellschaft Perfluoroalkyl-containing complexes, process for their production as well as their use

Also Published As

Publication number Publication date
PE20070363A1 (es) 2007-04-20
CA2615434A1 (en) 2007-01-25
EP1904462A2 (de) 2008-04-02
WO2007009637A2 (de) 2007-01-25
DOP2006000166A (es) 2007-02-28
WO2007009637A3 (de) 2007-05-10
US20070020183A1 (en) 2007-01-25
TW200740777A (en) 2007-11-01
JP2009509915A (ja) 2009-03-12
GT200600314A (es) 2007-07-05

Similar Documents

Publication Publication Date Title
UY29663A1 (es) Complejos metalicos con contenido de perfluoroalquilo, procedimientos para su preparacion, así como su uso
CR9645A (es) Complejos con contenido de perfluoroalquilo, procedimientos para su preparacion asi como su uso
ECSP11011439A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
UY29469A1 (es) Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos.
CR10654A (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados
UY29375A1 (es) 5-alcoxialquil-6-alquil-7-amino-azolopirimidinas, un procedimiento para su obtención y el uso de las mismas para combatir hongos nocivos,así como productos que las contienen.
NO20071880L (no) Diagnostic Compounds
UY32049A (es) Inhibidores de cmet
CR11861A (es) Compuestos organicos
UY32292A (es) Agonistas de s1p1 y métodos de preparación y uso
CO6430468A2 (es) Anticuerpos anti-fcrh5 e inmunoconjugados y métodos de uso
CR20120264A (es) Compuestos
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
AR105592A1 (es) b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS
CL2009001686A1 (es) Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados.
UY29434A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como inhibidores de la inflamacinn
ECSP11010816A (es) Nuevos Compuestos
BR112015006370A8 (pt) composto citotóxico, sua mistura e sal farmaceuticamente aceitável, sal/solvente complexo, metal complexo, exceto um com qualquer de fe2+, fer+, co2+, complexo solvente ou pró-fármico, bem como seu uso e composição o compreendendo
ECSP11011217A (es) Microbiocidas nuevos.
UY31700A (es) Tiazolil-dihidro-indazoles
UY31426A1 (es) Compuestos fungicidas, procedimientos para su obtención y su uso para combatir hongos nocivos asi como agentes que los contienen
EA201000141A1 (ru) Новые триазены для лечения рака
CO6460762A2 (es) 5-alquinil-piridinas
CU20090059A7 (es) Quelatos metálicos con radical peg perfluorado, método para su preparación y su uso

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160905